Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies
Fusar-Poli P, Berger G
Journal of clinical psychopharmacology · 76 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2012-02-24 · J Clin Psychopharmacol · vol. 32 · número 2 · págs. 179–185
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 119 citas · más que el 99% de estudios similares · 13.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 31 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Schizophrenia research and treatment · Tryptophan and brain disorders
- Palabras clave
- eicosapentaenoic acid, omega-3 fatty acids, schizophrenia, antipsychotic augmentation, psychotic symptoms, treatment-resistant psychosis, relapse prevention
- MeSH
- humans, eicosapentaenoic acid, treatment outcome, regression analysis, psychotic disorders, schizophrenia, dose-response relationship, drug, adult, female, male, randomized controlled trials as topic
2 autores
- Paolo Fusar‐Poli🇬🇧 · autor de correspondenciaKing's College London
- Gregor Emanuel Berger🇦🇺The University of Melbourne
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Omega-3 fatty acids, in particular, eicosapentaenoic acid (EPA) have been suggested as augmentation strategies in the treatment of schizophrenia and related psychosis. Published results are conflicting, and the antipsychotic efficacy of such augmentation strategies is not well established.
Methods
Double-blind, randomized, placebo-controlled studies using purified or EPA-enriched oils in established schizophrenia were included in a meta-analysis. The effect size of EPA on psychotic symptoms was measured using Hedges' g. Publication bias was assessed with funnel plots and Egger's intercept. Heterogeneity was assessed with Q statistic and I index. Influence of moderators was assessed with meta-regression analyses in Comprehensive Meta-analysis Software version 2.
Results
The database included 167 schizophrenic subjects under the placebo arm (mean age, 37 [SD, 9.7] years; 37% females) matched with 168 schizophrenic subjects under the EPA arm (mean age, 37 [SD, 7.9] years; 36% females) (t tests P > 0.05). Meta-analysis showed no consistent significant effect for the EPA augmentation on psychotic symptoms (Hedges' g = 0.242; 95% confidence interval, 0.028-0.512, Z = 1.7531, P > 0.05). There were no significant effects for moderator variables such as age, sex, and EPA dose used in the trials. Heterogeneity across studies was small and statistically non significant (Q = 9.06; P = 0.170; I = 33.81).
Conclusions
Meta-analysis of randomized controlled trials on symptomatic outcome revealed no beneficial effect of EPA augmentation in established schizophrenia. However, no conclusion can be made for medium- to long-term effects of EPA in schizophrenia, in particular on relapse prevention in the early course of psychotic disorders.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.